In consultation: Guidance and quality standards
Showing 11 to 18 of 18
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596] | Draft guidance | Technology appraisal guidance | |
| Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514] | Final draft guidance | Technology appraisal guidance | |
| Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575] | Final draft guidance | Technology appraisal guidance | |
| Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Topical tapinarof for treating mild to severe plaque psoriasis ID6712 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529] | Draft guidance | Technology appraisal guidance | |
| Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |